January | 2026
Key Highlights of the ABC WIN Seminar 2026 featuring the Acandis® Portfolio
The ABC WIN Seminar 2026 once again proved to be an important forum for scientific exchange and collaboration in neurointervention. At this year’s meeting, Acandis® was proud to see multiple expert physicians highlight their experience with the Acandis® portfolio, reinforcing the company’s long‑term commitment to clinically driven innovation and meaningful patient outcomes.
Strong Clinical Interest across the Acandis® Portfolio
Throughout the programme, Acandis® technologies were discussed in the context of real‑world clinical practice, reflecting a growing interest in solutions designed to address complex neurovascular challenges. Presentations emphasised how thoughtful device design and evidence‑based development can support physicians in daily decision‑making across a range of indications.
Acandis® Topics Presented at ABC WIN
The following Acandis®‑related topics were presented and discussed during the meeting, each highlighting a distinct aspect of the company’s research and development focus.
RESOLVE: SiREX® Stent for the Treatment of Pulsatile Tinnitus due to SymptOmatic Lateral Venous Sinus Stenosis
Dr. Nicolas Bricout, Lille University Hospital, France
The SiREX® Stent was specifically designed for the treatment of disabling pulsatile tinnitus caused by lateral sinus stenosis, addressing a significant unmet clinical need. Encouraging early results were reported, highlighting the potential of the SiREX® Stent to redefine the standard of care for this patient population.
CARESTAR: High coverage CARotid stenting vs. medical management alone to prevent EmboliSm from symptomatic non-stenotic cARotid disease (SyNC)
PD Dr. Hannes Nordmeyer, Städtisches Klinikum Solingen, Germany
The CARESTAR study will assess whether carotid stenting with the CARESTO® heal device can reduce embolic events and improve long-term neurological outcomes compared with medical therapy alone, in patients with mild carotid stenosis (10-49%).
REheal: Flow Diversion of Intracranial Aneurysms with DERIVO® 2heal®
PD Dr. Maxim Bester, Universitätsklinikum Hamburg-Eppendorf, Germany
Key takeaways and insights from this prospective study evaluating the DERIVO® 2heal® Embolisation Device for the treatment of intracranial aneurysms were presented. The observations focused on technical aspects, practical experience in the clinical setting, and factors relevant for the long‑term assessment of safety and performance. The study provides important perspectives on the use of the system and contributes to the growing understanding of the role of coated flow diverters in neurointerventional therapy.
Stent-Assisted Coiling Using Coated vs Uncoated ACCERO® stents
PD Dr. Maxim Bester, Universitätsklinikum Hamburg-Eppendorf, Germany
The interim results from this study provide valuable insights into the robust performance and safety of the ACCERO® (heal) stents and underscore the promising benefits associated with the unique HEAL coating.
Preclinical Results of DERIVO® 2heal®
Dr. Jonathan Cortese, Bicêtre Hospital Paris, France
The pathology of aneurysms involves both mechanical and biological components. Accordingly, effective treatment strategies should aim not only to provide mechanical exclusion of the aneurysm but also to promote biological arterial healing. The preclinical results of DERIVO® 2heal® of a comprehensive model provide promising insights into promoting endothelialisation and improving treatment success.
RECHRUT: Rescue Stenting with CREDO® heal
PD Dr. Hannes Nordmeyer, Städtisches Klinikum Solingen, Germany
The RECHRUT study is assessing key aspects of safety, visibility, and efficacy in early rescue stenting with the CREDO® heal Stent, offering valuable insights for future clinical use.
Collaboration at the Heart of Progress
A recurring theme at ABC WIN was the importance of collaboration between clinicians, researchers, and industry partners. The meeting provided a platform for peer‑to‑peer exchange and open discussion, reinforcing the shared goal of advancing patient care through responsible innovation.
Acandis® sincerely thanks the physicians who contributed their expertise, as well as the ABC WIN organisers for creating an environment that encourages scientific dialogue and progress. Events like ABC WIN Seminar continue to play a vital role in shaping the future of neurointerventional therapy.
Find additional information on LinkedIn.